ARAZLO
Google image searchProduct monograph
Active ingredient
tazarotene, 0.045 %/W/W
DIN: 02517868
Dosage form(s): LOTION
Route(s) of administration: TOPICAL
Schedule: Prescription
Company: BAUSCH HEALTH, CANADA INC.
Date: 16-SEP-2021
ATC:
- D05 — ANTIPSORIATICS (ATC, ATC/DDD, )
- D05A — ANTIPSORIATICS FOR TOPICAL USE (ATC, ATC/DDD)
- D05AX — Other antipsoriatics for topical use (ATC, ATC/DDD)
- D05AX05 — TAZAROTENE (ATC/DDD)
Reference brand drug: Tazorac, Arazlo, Duobrii
